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Abstract
Introduction: Vascular endothelial growth factor is a potent stimulator of
angiogenesis. Children with cyanotic congenital heart disease often experience
the development of widespread formation of collateral blood vessels, which may
represent a form of abnormal angiogenesis resulting in increased morbidity and
mortality. We undertook the present study to determine whether children with
cyanotic congenital heart disease have elevated serum levels of vascular
endothelial growth factor compared to children with acyanotic heart disease.
Material and methods: Serum was obtained from 35 children with cyanotic
congenital heart disease and 30 children with acyanotic heart disease. Vascular
endothelial growth factor levels were measured in the serum of these patients
by sandwich enzyme immunoassay.
Results: Vascular endothelial growth factor was significantly elevated in children
with cyanotic congenital heart disease compared to children with acyanotic
heart disease (150.3 ±48.1 vs. 85.4 ±18.7 pg/ml, respectively, p < 0.001). In the
cyanotic group, oxygen saturation (SaO2) was negatively correlated with VEGF
(r = –0.631, p < 0.001) while haemoglobin was positively correlated (r = 0.781,
p = 0.007). No significant correlations were found in the acyanotic group.
Conclusions: Children with cyanotic congenital heart disease have elevated
systemic levels of vascular endothelial growth factor directly related to the
degree of cyanosis (SaO2 and haemoglobin levels). These findings suggest that
the widespread formation of collateral vessels in these children may be mediated
by vascular endothelial growth factor. 
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Introduction
Angiogenesis, the formation of new capillary blood vessels, contributes
to progression of a variety of diseases, such as tumour dissemination [1],
rheumatoid arthritis [2, 3], and diabetic retinopathy [4, 5]. On the other
hand, in conditions such as ischaemic cardiovascular disease [6, 7], ulcer
healing [8, 9], and wound healing [10, 11], it is a physiological response to
recover from organ injury because the restoration of blood flow is essential
for oxygen and nutrient delivery to the healing site. Remarkable amounts
of neovascularization develop in patients with cyanotic congenital heart
disease who have low pulmonary blood flow and systemic cyanosis [12,
13]. The neovascularization in these patients has a compensatory role in
systemic hypoxia and may be important for organ survival.
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Abnormal vessel proliferation in these children
may take several forms, including systemic-to-
pulmonary collateral arteries [14-17], systemic-to-
pulmonary venous collaterals [18], systemic 
venous collateral channels after bidirectional
cavopulmonary anastomosis [19, 20], and
pulmonary arteriovenous malformations [21]. It has
been postulated that vascular endothelial growth
factor (VEGF) may be responsible for the abnormal
vessel proliferation. Several studies have
demonstrated that VEGF expression is induced by
hypoxia [22-24]. It has also been reported that
children with cyanotic congenital heart disease have
elevated systemic levels of VEGF [25]. These studies
included a small number of patients and need to
be validated.
We hypothesized that VEGF may mediate the
abnormal angiogenesis which is seen in children
with cyanotic congenital heart disease. Thus, the
purpose of this study was to determine whether
children with cyanotic congenital heart disease have
elevated serum levels of VEGF compared to children
with acyanotic heart diseases, and also whether the
VEGF levels correlate with the degree of cyanosis.
Material and methods
From September 2007 to March 2008, 65
consecutive children were prospectively entered
into the study. Oral consent was obtained from the
parents of the children involved in the study. The
children’s age ranged from 10 months to 10.5 years.
The children were divided into two groups: those
with cyanotic congenital heart disease (CHD) and
those with acyanotic congenital heart diseases. All
the patients were recruited from the Paediatric and
Cardiology Departments of Cairo University
Hospitals. 
The first group consisted of 35 children 
(19 females, 16 males; age range: 10 months-9.8
years) with cyanotic CHD, while the second group
included 30 children (16 females, 14 males; aged
between 12 months and 10.5 years) with acyanotic
congenital heart disease. 
All the children were subjected to the following: 
• full history and clinical examination, including
weight and height; the nutritional status of the
patients was assessed by BMI [weight (kg)/height
(m2)];
• laboratory investigations:
– haemoglobin concentration and haematocrit,
– arterial oxygen saturation: arterial oxygen
saturation (SaO2) was analysed in blood
samples drawn from the peripheral vessels,
– level of VEGF in serum: blood samples for VEGF
analyses were withdrawn by standard
venipuncture and were centrifuged for 10 min
at 5000 rpm and then serum samples were
stored at –20°C until the time of analysis;
serum VEGF level was measured with
sandwich enzyme immunoassay using
commercially available kits (Human VEGF,
Cytimmune Sciences Inc., Rockville, MD, USA),
– other investigations included kidney function,
complete blood picture and prothrombin time
and concentration;
• chest X-ray: PA and lateral views;
• twelve-lead electrocardiogram;
• echocardiography: using a Sonos 5500 ultrasound
system (HP Hewlett Packard), with a 5 MHz
transducer for children. M-mode and 2-dimen  -
sional examinations were performed from the
standard subcostal, parasternal and apical
approaches; Doppler (pulsed wave and continuous
wave) and colour Doppler mapping were also used
to reach the diagnosis;
• cardiac catheterization: using a Philips biplane
cardiac catheterization laboratory:
– this was performed in:
– patients with pulmonary atresia: mainly to
determine the origin and distribution of
collaterals,
– patients with tetralogy of Fallot: to define
the coronary arteries and to determine the
left ventricular diastolic volume and index;
also to determine the origin and distribution
of collaterals.
Both right and left sided cardiac catheterization
was performed and pressure was measured in all
chambers and from the pulmonary artery and
pulmonary veins (wedge pressure). Saturation in all
the chambers was also performed to detect shunts.
Clinical diagnoses in both groups are listed in Table I.
Exclusion criteria included:
• patients with acute illness;
• patients who were critically ill, including those
with moderate to severe malnutrition, according
to the growth indices (Table II);
•  patients scheduled for surgery during the
withdrawal of blood samples;
• patients with pulmonary hypertension.
Data were analysed by the Statistics Package for
Social Sciences Statistical Software (SPSS) 11.0. All
results were expressed as the mean value ±
standard deviation. Student’s t-test was used for
comparisons between the two groups. The
correlations between the groups were assessed by
Pearson correlation. A value of p < 0.05 was
interpreted as indicating statistical significance.
Results
As regards the general characteristics of patients,
no significant difference was found between the
groups for age (p = 0.652), body weight or height
(Table II). Nutritional status of the two groups was
assessed by body weight, height and BMI. Body
mass index levels were within the normal range inVascular endothelial growth factor in children with cyanotic and acyanotic and congenital heart disease
the cyanotic group and acyanotic group, showing
absence of moderate or severe malnutrition in both
groups; however, BMI levels were significantly lower
in the cyanotic as compared to the acyanotic group
(p < 0.001) (Table III).
Serum VEGF was measured in all subjects 
(Table IV). The mean VEGF level was significantly
higher in the cyanotic group as compared to the
acyanotic group (150.3 ±48.1 vs. 85.4 ±18.7 pg/ml,
respectively, p < 0.001).
SaO2 values were significantly lower in the
cyanotic group than those in the acyanotic group
(80.4 ±2.4 and 97.5 ±1.9, respectively; p < 0.001).
The SaO2 values were compared with the VEGF
level in each group. In the cyanotic group, SaO2 was
negatively correlated with VEGF (r = –0.631, 
p < 0.001). No significant correlation was noted
between VEGF and SaO2 in the acyanotic group
(Table IV).
Haemoglobin levels were significantly different
between the groups (13.5 ±1.7 and 11.81 ±0.97,
respectively; p < 0.001). Haemoglobin levels were
compared with VEGF in each group. Haemoglobin
was positively correlated (r = 0.781, p = 0.007) with
VEGF in the cyanotic group.
No correlations were noted between the VEGF,
haemoglobin and SaO2 levels in the acyanotic group
(Table V).
Discussion
The present study demonstrated that VEGF level
was significantly elevated in children with cyanotic
heart disease compared to children with acyanotic
GroupD iagnosis Number of patients Female/male
Cyanotic group I (n = 35) Tetralogy of Fallot 20 19/16
Double outlet RV 6
TGA + VSD 7
PA + VSD 2
Acyanotic group II (n = 30) VSD 18 16/14
ASD 8
PDA 4
Table I. Diagnoses in cyanotic and acyanotic groups
RV – right ventricle, TGA – transposition of great arteries, VSD – ventricular septal defect, PA – pulmonary atresia, ASD – atrial septal defect, 
PDA – patent ductus arteriosus
Nutritional status Weight/age Height/age Weight/height % IBW
Wasting Normal or low Normal < 5th percentile < 85-90%
Stunting < 5th percentile < 5th percentile Normal Normal
Mild malnutrition Normal or low Normal < 5th percentile 81-90%
Moderate malnutrition Normal or low Normal < 5th percentile 70-80%
Kwashiorkor Normal or low Normal or low Normal (oedema) Normal
Table II. Indices used to determine the nutritional status of the children included in the study [26]
IBW – ideal body weight
VEGF
Figure 1. Vacular endothelial growth factor levels in
cyanotic and acyanotic groups (p < 0.001)
Cyanotic
Acyanotic
Cyanotic Acyanotic P
Age [year] 3.1 ±1.6 3 ±1.7 0.652
Body weight [kg] 13.5 ±4.1 15.1 ±2.5 0.327
Height [cm] 93.1 ±14.6 95.2 ±12.1 0.738
BMI [kg/m2] 14.3 ±0.4 16.7 ±0.7 < 0.001*
Table III. Demographic data in cyanotic and acyanotic
groups
BMI – body mass index, data are mean ± standard deviation
*Indicates significant difference
160
140
120
100
80
60
40
20
0
Arch Med Sci 2, April / 2010 223224 Arch Med Sci 2, April / 2010
heart disease. These results are similar to previous
studies [25, 32]. This elevated level of VEGF in the
cyanotic group can be explained by the hypoxia,
which is a strong stimulus for angiogenesis and
leads to upregulation of VEGF. The lack of correlation,
in the acyanotic group, between the VEGF level and
the oxygen saturation or the haemoglobin level
suggests that the main stimulus for VEGF elevation
was the cyanosis present (low oxygen saturation
and elevated haemoglobin levels).
The importance of neovascular formation in
children with cyanotic heart disease is that it
increases morbidity and mortality. An example of
this is the development of aortopulmonary
collateral arteries associated with pulmonary
atresia. This may cause a number of problems,
including significant left to right shunting,
progressive obliteration after unifocalization
procedures, and pulmonary “steal” from systemic
blood flow during cardiopulmonary bypass. The
management of children with cyanotic congenital
heart disease may be complicated by the
development of these vascular lesions and may
require interventional cardiac catheterization or
surgical treatment [25].
Vascular endothelial growth factor is a potent
mitogen acting specifically on vascular endothelial
cells, and is known to play a role in angiogenesis in
widely divergent circumstances, such as embryonic
development [27], wound healing [9-11], tumour
growth [28], rheumatoid arthritis [2, 3, 29], and
ischaemic retinopathy [30]. Vascular endothelial
growth factor has been demonstrated to induce
angiogenesis, endothelial cell proliferation, and
migration, thereby promoting blood vessel growth.
Recent studies have demonstrated that
angiogenesis, facilitated by administration of
angiogenic growth factors as in recombinant protein
therapy or gene transfer, may be augmented in
animal models of myocardial ischaemia [31].
Therapeutic angiogenesis with VEGF was recently
performed in order to reduce the unfavourable
tissue effects caused by ischaemia [32]. 
The present study represents a preliminary
attempt to identify factors that may have an
impact on manifestations of cyanotic congenital
heart disease. Vascular endothelial growth factor
appears to be systemically elevated in patients
with chronic cyanosis and may contribute to the
formation of extensive collateral vessels that
sometimes develop in these children. Issues
related to the exact origin of these factors are not
specifically answered by this study. However,
these findings may have broader implications
regarding the pathophysiological features of
cyanotic heart disease, while further study of
affected children may aid in understanding the
control mechanisms of angiogenesis.
Limitations: a limitation of this study was the
broad variation in circulatory dynamics within the
cyanotic group. The cyanotic group consisted of
patients with various congenital heart diseases,
such as tetralogy of Fallot causing decreased
pulmonary blood flow, or a double outlet right
ventricle causing increased pulmonary blood flow.
Variability of the underlying haemodynamics and
anatomy of the cyanotic group may make
consistent analysis impossible. Vascular endothelial
growth factor elevation may depend not only on
systemic oxygen saturation but also on other
factors, such as cytokines. More detailed studies
are required to resolve this question.
Also, VEGF elevation may be related to the
function of time. It was difficult for us to
standardize an age limit for our cohort of patients
(e.g. 2-year old children with CHD). Also the normal
level of VEGF according to age is still uncertain [33].
Our study was also limited by the number of
patients and the lack of visualization of the
arteriovenous connections within the cyanotic
group.
In conclusion, children with cyanotic heart
disease have elevated levels of VEGF (compared to
children with acyanotic heart disease) and this
elevation is directly correlated with the
haemoglobin concentration and inversely correlated
with the level of hypoxia. These findings suggest
that the widespread formation of collateral vessels
in these children may be mediated by vascular
endothelial growth factor. 
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Cyanotic Acyanotic Value of p
VEGF [pg/ml] 150.3 ±48.1 85.4 ±18.7 < 0.001*
Haemoglobin [g/l] 13.5 ±1.7 11.81 ±0.97 < 0.001*
SaO2 [%] 80.4 ±2.4 97.5 ±1.9 < 0.001*
Table IV.  Vascular endothelial growth factor,
haemoglobin and arterial oxygen saturation in
cyanotic and acyanotic groups
VEGF – vascular endothelial growth factor, SaO2 – arterial oxygen
saturation, data are mean ± standard deviation
*Indicates significant difference
Cyanotic VEGF Acyanotic VEGF
Rp R p
Haemoglobin 0.781 0.007 0.27 0.217
SaO2 [%] –0.631 < 0.001* –0.321 0.347
Table V. Correlation coefficients in cyanotic and
acyanotic groups
VEGF – vascular endothelial growth factor, SaO2 – arterial oxygen
saturation
*Indicates significant correlationArch Med Sci 2, April / 2010 225
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